Coral Laboratories Ltd

Quarterly revenue volatile between ₹13.55–32.23 Cr (Jun 2023–Sep 2024) and profit swings from ₹1.84–8.81 Cr; Q4 FY2025 shows revenue flat at ₹28.14 Cr but OPM collapsed to 9.56% from 27.49%, raising questions about cost control.

EPS highly inconsistent (₹5.16–24.64 across quarters); Mar 2025 shows 0 EPS despite ₹2.83 Cr profit — verify whether tax impact, one-time charges, or capital changes explain this disconnect.

1-year return of 5.12% lags broader market; combined with earnings volatility, this suggests limited investor confidence and potentially constrained valuation multiple.

ROE and D/E unavailable; cannot assess return on equity or leverage — verify capital structure and debt levels to assess financial stability and growth capacity.

Sep 2024 peak revenue of ₹32.23 Cr (up 138% from Jun 2023 low of ₹13.55 Cr) shows scaling capability; verify whether this reflects sustained market demand and forecast durability.

Quarterly OPM ranged 9.56–33.93%; if revenue expands while cost discipline holds (as Jun 2024's 33.93% demonstrated), profit would compound significantly — verify product mix and fixed-cost structure.

Dividend payouts across five years (2025, 2024, 2019, 2018, 2017) evidence consistent cash generation; verify capital allocation between distribution to shareholders and reinvestment in growth.

Company operates in Pharmaceuticals within Healthcare sector; verify therapeutic focus, distribution breadth, and addressable market growth to assess sector tailwind capture.